Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this 'adaptive response' in mice

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 6, 1999, Pages 615-629

  Rakhit, Ashok ^a,b,c   Yeon, Mitchell M ^a,b,c   Ferrante, Jessica ^a,b,c   Fettner, Scott ^a,b,c   Nadeau, Rosemary ^a,b,c   Motzer, Robert ^a,b,c   Bukowski, Ronald ^a,b,c   Carvajal, Daisy M ^a,b,c   Wilkinson, Victoria L ^a,b,c   Presky, David H ^a,b,c   Magram, Jeanne ^a,b,c   Gately, Maurice K ^a,b,c  

^a HOFFMANN LA ROCHE INC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR; MESSENGER RNA; RECOMBINANT INTERLEUKIN 12;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; MALE; MOUSE; MULTICENTER STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEPTOR UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANIMALS; BETA 2-MICROGLOBULIN; CARCINOMA, RENAL CELL; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 0033054559     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)90083-8     Document Type: Article

References (39)

1. 1. Hendrzak JA, Brunda MJ. Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab Invest 1995;72:619-37.
2. 2. Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM, et al. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1994;1:187-96.
3. 3. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
4. 4. Gately MK, Renzetti LM, Magram J, Stem AS, Adorini L. Gubler U, et al. The interleukin-12/interleukin-12 receptor system: role in normal and pathological immune responses. Annu Rev Immunol 1998;16:495-521.
5. 5. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
6. 6. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697-706.
7. 7. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
8. 8. Sypek JP, Chung CL, Mayor SEH, Subramanyam JM, Goldman SJ, Sieburth DS, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type I immune response. J Exp Med 1993;177:1797-802.
9. 9. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995;182:1527-36.
10. 10. Wittes RE. Grading of toxicity, appendix A. In: Manual of oncologic therapeutics. Philadelphia: JB Lippincott; 1991. p. 445-8.
11. 11. Nadeau RR, Ostrowski C, Ni-Wu G, Liberato DJ. Pharmacokinetics and pharmacodynamics of recombinant human interleukin-12 in male rhesus monkeys. J Pharmacol Exp Ther 1995;274:78-83.
12. 12. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982. p. 409-17.
13. 13. Wu CY, Ferrante J, Gately MK, Magram J. Characterization of IL-12 receptor β1 chain (IL-12Rβ1)-deficient mice. IL-12Rβ1 is an essential component of the functional mouse IL-12 receptor. J Immunol 1997;159:1658-65.
14. 14. Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U, Hubbard BR, Murphy M. Administration of recombinant. IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol 1994;6:157-67.
15. 15. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, et al. IL-12-deficient mice are defective in IFN-γ production and type I cytokine responses. Immunity 1994;4:471-81.
16. 16. Gately MK, Chizzonite R, Presky DH. Measurement of human and mouse interleukin 12. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology; vol 1. New York: John Wiley; 1995.6.16. p. 1-15.
17. 17. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984;81:1991-5.
18. 18. Chua AO, Wilkinson VL, Presky DH, Gubler U. Cloning and characterization of a mouse IL-12 receptor-β component. J Immunol 1995;155:4286-94.
19. 19. Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu CY, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996;93:14002-7.
20. 20. Gray PW, Goeddel DV. Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci USA 1983;80:5842-6.
21. 21. Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, et al. Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994;153:128-36.
22. 22. Chizzonite R, Truitt T, Desai BB, Nunes P, Podlaski FJ, Stem AS, et al. IL-12 receptor; I: characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol 1992;148:3117-24.
23. 23. Motzer R, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, et al. Phase I trial of subcutaneous recombinant interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998;4:1183-91.
24. 24. Gately MK, Brenda MJ. Interleukin-12: a pivotal regulator of cell-mediated immunity. In: Kurzrock R, Talpaz M, editors. Cytokines: interleukins and their receptors. Norwell: Kluwer Academic Publishers; 1995. p. 341-66.
25. 25. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997;90:2541-8.
26. 26. Sacco S, Heremans H, Echtenacher B, Buurman WA, Amraoui Z, Goldman M, et al. Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids. Blood 1997;90:4473-9.
27. 27. Coughlin CM, Wysocka M, Trinchieri G, Lee WMF. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 1997;57:2460-7.
28. 28. Tare NS, Bowen S, Warrier RR, Carvajal DM, Benjamin WR, Riley JH, et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 1995;15:377-83.
29. 29. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993;259:1739-42.
30. 30. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
31. 31. Wu CY, Warrier RR, Carvajal DM, Chua AO, Minetti LJ, Chizzonite R, et al. Biological function and distribution of human interleukin-12 receptor β chain. Eur J Immunol 1996;26:345-50.
32. 32. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989;170:827-45.
33. 33. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, et al. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991;173:869-79.
34. 34. Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, Woerly G, et al. Role of interferon-γ, in interleukin 12-induced pathology in mice. Am J Pathol 1995;147:1693-707.
35. 35. Morris SC, Madden KB, Adamovicz JJ, Gause WC, Hubbard BR, Gately MK, et al. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 1994;152:1047-56.
36. 36. Gerosa F, Paganin C, Peritt D, Paiola F, Scupoli MT, Aste-Amezaga M, et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-γ and interleukin-10. J Exp Med 1996;183:2559-69.
37. 37. Windhagen A, Anderson DE, Carrizosa A, Williams RE, Hafler DA. IL-12 induces human T cells secreting IL-10 with IFN-γ. J Immunol 1996;157:1127-31.
38. 38. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor α are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993; 90:3725-9.
39. 39. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178: 1041-8.